What to Know About Myrbetriq (Mirabegron)

A Prescription Medication for Treating Overactive Bladder

Table of Contents
View All
Table of Contents

Myrbetriq (mirabegron) treats overactive bladder, a condition in which the bladder muscles contract involuntarily, causing a frequent urge to urinate. Myrbetriq is a beta-3 adrenergic agonist that works by relaxing the smooth muscles surrounding the bladder so they can hold more urine. It is an extended-release tablet that may be used alone or in combination with VESIcare (solifenacin succinate).

Senior female doctor discusses medication with female patient
SDI Productions / Getty Images


To treat overactive bladder, Myrbetriq relaxes the detrusor smooth muscle of the bladder during the storage phase of the bladder’s fill-void cycle to increase the bladder's capacity. It does this by activating the beta-3 adrenergic receptors.

Myrbetriq may be used in combination with VESIcare when symptoms aren’t resolved with just one medication. VESIcare, an antimuscinaric drug, helps prevent contraction and spasm of the muscles in the bladder.

Your healthcare provider may suggest combination therapy with Myrbetriq if you are already taking VESIcare and still having symptoms. This may prevent side effects from higher dosages of VESIcare. (For some, VESIcare may cause anticholinergic central nervous system effects, including headaches, confusion, drowsiness, and hallucinations.) Your healthcare provider may monitor you for signs of urinary retention if you're taking both Myrbetriq and an antimuscinaric drug like VESIcare.

Ongoing Research

Myrbetriq is being studied to determine if it has an effect on erectile dysfunction. A study done in 2019 found that mirabegron improved erectile dysfunction in diabetic rats. Results of research on humans are inconsistent, with one 2020 study finding no beneficial effect of mirabegron on erectile dysfunction.

Before Taking

The first line of treatment for overactive bladder usually includes behavioral strategies, such as bladder training, bladder control strategies, pelvic floor muscle training, and fluid management.

One strategy is a bladder training program, which involves urinating on a set schedule whether you feel the urge to go or not. Other techniques include keeping track of fluids, limiting caffeine, and strengthening your bladder muscles through pelvic floor exercises (Kegel exercises).

If these techniques aren’t successful, your healthcare provider may suggest medication. You’ll probably start with one medication to see if it reduces your symptoms. If you’ve seen some improvement on one medication for a trial period, but still have bothersome symptoms, your healthcare provider may suggest adding Myrbetriq or anticholinergic medication such as VESIcare, Ditropan, Toviaz, or Sanctura.

Let your healthcare provider know if you’re currently taking any medications, supplements, and vitamins. While some drugs may cause minor interactions, others may be contraindicated for use with Myrbetriq. Your healthcare provider will discuss the risks and benefits of using Myrbetriq with you.

Precautions and Contraindications

If may not be safe to take Myrbetriq if you have certain health conditions. Your healthcare provider may decide that Myrbetriq isn’t appropriate for you or that your condition should be monitored while taking it.

Some contraindications for taking Myrbetriq include:

  • Allergy/sensitivity to Myrbetriq: You shouldn’t take Myrbetriq if you’ve had an allergic reaction or hypersensitivity to mirabegron or any of its inactive ingredients: polyethylene oxide, polyethylene glycol, hydroxypropyl cellulose, butylated hydroxytoluene, magnesium stearate, hypromellose, yellow ferric oxide, and red ferric oxide.
  • Bladder outlet obstruction: Some patients with bladder outlet obstruction have reported problems with urinary retention when taking Myrbetriq. However, a study of 200 men with bladder outlet obstruction found that mirabegron was not associated with acute urinary retention after 12 weeks of treatment. If you have bladder outlet obstruction, your healthcare provider may prescribe Myrbetriq with caution and monitor your condition.
  • Uncontrolled hypertension: Myrbetriq is not recommended if you have severe uncontrolled hypertension, since one of the side effects can be an increase in blood pressure. Your healthcare provider may suggest another treatment if your systolic blood pressure is greater or equal to 180 millimetres of mercury (mmHg) or your diastolic blood pressure is greater than or equal to 110 mmHg.
  • Kidney conditions: Myrbetriq is not recommended if you have end-stage renal disease or if you require hemodialysis. Patients with severe renal impairment should not exceed 25 milligrams (mg) of Myrbetriq per day.
  • Liver problems: Myrbetriq should not be used if you have severe hepatic impairment. Patients with moderate hepatic impairment should not exceed a daily dose of 25 mg.

Let your healthcare provider know if you are pregnant, planning to become pregnant, or breastfeeding before taking Myrbetriq. Some data from animal studies indicates maternally toxic exposures in rats, decreased fetal weight, and increased fetal mortality. However, the risk of birth defects and miscarriages for humans is unknown as there have been no such studies done on people.


Myrbetriq is available as an extended-release tablet in two different doses: 25 mg and 50 mg. According to the manufacturer, the recommended dosage to start with is 25 mg once a day, either alone or in combination with a daily dose of 5 mg of solifenacin succinate.

You should notice the effects of Myrbetriq within eight weeks. Depending on your results, your healthcare provider may suggest increasing the dosage to 50 mg once a day, either alone or in combination with your daily 5 mg dose of solifenacin succinate. Patients with severe renal impairment or moderate hepatic impairment shouldn’t exceed 25 mg of Myrbetriq once daily.

All listed dosages are according to the drug manufacturer. Check your prescription and talk to your healthcare provider to make sure you are taking the right dose for you.

How to Take and Store

You should take Myrbetriq with water, with or without food. It should be swallowed whole and not chewed, divided, or crushed.

If you miss a dose of Myrbetriq, begin taking it again the next day. Do not take two doses of it on the same day.

Myrbetriq should be stored in a cool place (between 59 and 86 degrees F). Keep the bottle closed and out of reach from children.

If you take more Myrbetriq than prescribed at one time, call your healthcare provider or go to the emergency room. Myrbetriq at doses of up to 400 mg has caused palpitations, increased pulse rate, and increased blood pressure in healthy volunteers. In the event of an overdose, monitoring your pulse rate, blood pressure, and an electrocardiogram (ECG) is recommended.

Side Effects

Myrbetriq can cause side effects that range from mild to severe.


The most common side effects of Myrbetriq include:


Some side effects of Myrbetriq can be serious. Call your healthcare provider right away if you experience the following:

  • Increase in blood pressure
  • Inability to empty your bladder
  • Angioedema, or rapid swelling beneath the skin

If Myrbetriq causes an allergic reaction, call your healthcare provider right away or go to the emergency room. Symptoms may include difficulty breathing or swelling of the face, lips, throat, or tongue.

Warnings and Interactions

Myrbetriq can cause interactions with certain medications, including:

  • Coumadin (warfarin)
  • Lanoxin (digoxin)
  • Lopressor (metoprolol)
  • Norpramin (desipramine)
  • Mellaril (thioridazine)
  • Tambocor (flecainide)
  • Rythmol (propafenone)

Tell your healthcare provider about any medications you’re taking, including those for overactive bladder.

Your healthcare provider may prescribe both Myrbetriq with VESIcare at the same time. When taking a combination of these medications, there may be an increased risk of urinary retention. Let your practitioner know immediately if you have any trouble emptying your bladder or a weak urine stream.

Because Myrbetriq may increase blood pressure, it's recommended that your healthcare provider check your blood pressure periodically while you’re taking the medication.

Was this page helpful?
9 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Myrbetriq website.

  2. U.S. Food & Drug Administration. Myrbertriq label.

  3. Allison S, Gibson W. Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experienceTher Adv Urol. 2018;10(12):411-419. doi:10.1177/1756287218801282

  4. Yilmaz-Oral D, Kaya-Sezginer E, Askin D, Hamurtekin Y, Gur S. Mirabegron, A selective β3-adrenoceptor agonist causes an improvement in erectile dysfunction in diabetic ratsExperimental and Clinical Endocrinology & Diabetes. 2019. doi:10.1055/a-0869-7493

  5. Wu T, Shen Y, Lee W, Wang H, Chuang Y. Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptomsJournal of the Chinese Medical Association. 2019:1. doi:10.1097/jcma.0000000000000208

  6. Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019 Sep;202(3):558-563. doi: 10.1097/JU.0000000000000309. Epub 2019 Aug 8. PMID: 31039103.

  7. American Urological Association. Diagnosis and Treatment of Non-Neurogenic Overactive Bladder (OAB) in Adults: an AUA/SUFU Guideline (2019).

  8. Nitti V, Rosenberg S, Mitcheson D, He W, Fakhoury A, Martin N. Urodynamics and safety of the β 3 -adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstructionJournal of Urology. 2013;190(4):1320-1327. doi:10.1016/j.juro.2013.05.062

  9. National Institutes of Health. Myrbetriq. DailyMed.